A study evaluating efficacy of cabazitaxel in patient with castration resistant prostate cancer.
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- 11 Oct 2017 New trial record
- 12 Sep 2017 Results assessing prognostic role for circulating tumor cells (CTCs) in castration resistant prostate cancer patient treated with cabazitaxel, were presented at the 42nd European Society for Medical Oncology Congress.